Heal or Harm: Body Protective Compound-157 in the Gray Zone

Body protective compound-157 (BPC-157), commonly referred to as the “Wolverine Peptide” by the fitness community, is synthesized from a molecule found in human gastric juice.¹ The compound is a pentadecapeptide having a chemical formula of C₆₂H₉₈N₁₆O₂₂.²

BPC-157 has gained popularity on social media via influencers claiming faster muscle recovery, ligaments, and tendons after its injection. When taken orally, it has potential to heal the gastrointestinal mucosa because the compound is not degraded by gastric acid.³ However, BPC-157 is not FDA-approved and has potential for enhanced immunogenicity, along with minimal establishment of purity, efficacy, or safety.⁴ Therefore, it carries a Category 2 bulk drug substance restriction.⁵ At present, there is limited human clinical literature available for BPC-157.⁶ Only 3 uncontrolled pilot studies with a combined sample size of 30 participants have been reported.⁶

Access to BPC-157

Legitimate access to BPC-157 requires a prescription from a health care professional who specializes in regenerative medicine, with access to a compounding pharmacy. The FDA's Pharmacy Compounding Advisory Committee is scheduled to review BPC-157 this summer to again determine bulk compounding use because the original restriction was met with resistance by industry professionals.⁵

However, this peptide is available for purchase on multiple websites because it is categorized as a research chemical. This easy accessibility has led to its consumption without medical guidance or consideration of adverse effects.

BPC-157 is most popular among younger individuals and those interested in fitness who assume the peptide will improve muscular recovery following an intense workout, along with reduced inflammation. Enhanced athletic performance is expected with the use of BPC-157, but in 2022, BPC-157 was prohibited by the World Anti-Doping Agency.⁷

Possible Mechanisms of Action

In preclinical data, BPC-157 has been proposed to have multiple actions on several core pathways. However, it is important to note that no receptor for BPC-157 has yet been identified, and the current evidence included below was obtained from animal studies.

In a 2025 literature review, 3 studies reported that no adverse effects were noted following BPC-157 injection in patients with intraarticular knee pain.⁸ However, established mechanisms and the long-term effects of BPC-157 in humans will require well-developed, large clinical trials.

Angiogenesis and Vasodilation

Through the VEGF signaling pathway, it appears that BPC-157 may stimulate blood vessel formation and enhance blood flow.^9,10 There is increased VEGFR2 phosphorylation, which leads to activation of other downstream pathways such as PI3K, ERK1/2, and nitric oxide (NO).^6,11 These mechanisms may explain how an individual recovers quickly following a workout, as there is increased blood flow to an injured muscle. BPC-157 may also activate the NO pathway through the Akt-eNOS axis.¹¹

Induction of the FAK-Paxillin Pathway

BPC-157 is thought to phosphorylate focal adhesion kinase (FAK) and paxillin. This signaling pathway is responsible for the regulation of cell survival, migration, and adhesion. FAK binds to paxillin and allows for cells to move via cytoskeletal reorganization. By this mechanism, cells can migrate into damaged areas of the body, promoting faster healing.^11,12

Stabilization of Acetylcholine Receptors

BPC-157 may affect the neuromuscular junction through stabilization of acetylcholine receptors, reversing the paralyzing effects of neuromuscular blockers such as succinylcholine. Through these synaptic functions, the peptide is thought to restore neurotransmission effects observed with muscular injury.^12,13

Decrease in Pro-inflammatory Cytokines

A significant decrease in tumor necrosis factor-α, IL-6, and interferon-γ has been observed with BPC-157.^12,14 This allows for a shift in macrophage activity from M1 (pro-inflammatory) to M2 (reparative).^12,15 Analgesia may be afforded by modulation of neurotransmitters, such as serotonin and dopamine.^14,15

Possible Adverse Effects

Users of the compound report local reactions such as redness, swelling, bruising, and pain following BPC-157 injection. Through BPC-157’s enhanced effects on the VEGF and NO pathways, dizziness and cardiovascular changes remain a concern for researchers.¹¹ Additionally, angiogenesis, involved in BPC-157 repair mechanism, promotes tumor growth and cancer metastasis.¹⁶ The possibility of these and additional systemic effects warrants large scale clinical trials to determine a safe and effective dose. Questions remain on how this peptide can affect individuals on concurrent medications and with preexisting conditions.

Conclusion

Although the therapeutic potential for BPC-157 shows promise in animal models, gaps in validated pharmacokinetic and safety methods remain barriers to optimal drug development. Due to its accessibility and popularity, clear warning labels about the peptide's lack of human evidence should be recommended to protect users and inform health care professionals of BPC-157’s potential risks.

REFERENCES

1. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4

2. Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066

3. Sikiric P, Gojkovic S, Krezic I, et al. Stable gastric pentadecapeptide BPC 157 may recover brain-gut axis and gut-brain axis function. Pharmaceuticals (Basel). 2023;16(5):676. doi:10.3390/ph16050676

4. Certain bulk drug substances for use in compounding that may present significant safety risks. FDA. Updated April 22, 2026. Accessed June 30, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

5. Is BPC-157 legal in 2026? FDA compounding status explained. Newtropin. June 17, 2026. Accessed June 30, 2026. https://newtropin.com/blog/is-bpc-157-legal-in-2026-fda-compounding-status-explained

6. BPC-157 human clinical trials (2025-2026): complete status & results. Peptide DB. December 27, 2025. Accessed June 30, 2026. https://peptide-db.com/guides/bpc-157-human-trials

7. WADA’s 2022 prohibited list now in force. World Anti-Doping Agency. January 1, 2022. Accessed June 30, 2026. https://www.wada-ama.org/en/news/wadas-2022-prohibited-list-now-force

8. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide-literature and patent review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185

9. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology. 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7

10. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. J Physiol Pharmacol. 2009;60 Suppl:191-196.

11. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7

12. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010

13. Vukojević J, Vrdoljak B, Malekinušić D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. doi:10.1002/brb3.1726

14. Kolovrat M, Gojkovic S, Krezic I, et al. Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. World J Hepatol. 2020;12(5):184-206. doi:10.4253/wjh.v12.i5.184

15. Knezevic M, Gojkovic S, Krezic I, et al. Occluded superior mesenteric artery and vein. Therapy with the stable gastric pentadecapeptide BPC 157. Biomedicines. 2021;9(7):792. doi:10.3390/biomedicines9070792

16. Yuan C, Demers A, Silva-Ortiz V, et al. From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. 2026;27(6):2876. doi:10.3390/ijms27062876